Revenue growth and profitability restored. Strategic review commences to unlock Company value
Current Performance Highlights:
· NPAT and EBITDA restored at $0.4 million and $1.3 million respectively for the half-year ending 31 December 2013, compared to $(0.8) million and $0.2 million in the previous corresponding period (PCP)
· Revenues shipped and invoiced were up 10% to $14.5 million, compared to $13.2 million for the PCP. The Company achieved sales-order growth over the PCP in the following areas: the US (up 26%), Japan (up 129%), Europe [excluding Germany] (up 44%) and the Middle East (5%)
· A number of breakout business divisions and products are being reviewed in the context of value and growth realisation.
· The Company’s previously articulated expansion strategy focused on a greater footprint in sleep diagnostics. Expansion into the neuro-monitoring and Long-Term EEG Monitoring (LTEM) market remains and will gain momentum as the Company builds on its improving underlying performance. In addition, the Company has commenced a strategic review of all its business areas, products and technologies to determine how best to unlock their value either individually or as a whole
Australian 24hr Customer Support Free Call 1800 244 773 USA - Compumedics USA Inc. USA Corporate HQ and Sales 6605 West WT Harris Blvd, Suite F, Charlotte, NC 28269, USA Toll Free: 877 717 3975 Tel : +1 704 749 3200 Fax: +1 704 749 3299
Germany - Compumedics Germany GmbH Europe HQ for Sleep, Neuroscience and Neuroscan Global HQ for Compumedics DWL